Completed PHASE1 INTERVENTIONAL NCT00003184

Vaccine Therapy in Treating Women With Metastatic Breast Cancer

Phase I Trial Using a CD80-Modified Allogeneic Breast Cancer Cell Line to Vaccinate HLA-A2-Positive Women With Breast Cancer

Sponsor: Providence Cancer Center, Earle A. Chiles Research Institute

Conditions Breast Cancer

Interventions BCG vaccine CD80 breast cancer vaccine sargramostim

Updated 5 times since 2017 Last updated: Apr 2, 2013 Started: Aug 31, 1996 Completion: Jul 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Providence Cancer Center, Earle A. Chiles Research Institute and has accumulated 5 data snapshots since 1996. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Aug 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Providence Cancer Center, Earle A. Chiles Research Institute

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Portland, United States